FIELD: medicine; pharmaceutics.
SUBSTANCE: invention relates to a compound having structural formula (VII), a pharmaceutical composition and use of the compounds in preparing a drug for treating a disease or disorder associated with JAK1.
EFFECT: novel compounds are obtained, which are safe and effective inhibitors of Janus kinase 1 and can be used in treating various diseases and disorders mediated by said activity, such as inflammatory diseases, immune-mediated diseases or cancer.
24 cl, 5 tbl, 50 ex
Title | Year | Author | Number |
---|---|---|---|
BENZAMIDE COMPOUNDS | 2019 |
|
RU2801647C2 |
TRICYCLIC COMPOUNDS, PHARMACEUTICAL COMPOSITION CONTAINING THEM AND USING THEM FOR TREATING IMMUNOLOGICAL AND ONCOLOGICAL COMPOUNDS | 2009 |
|
RU2545023C9 |
MODULATORS OF INTEGRATED STRESS SIGNALING PATH | 2017 |
|
RU2769327C2 |
IMIDAZOTRIAZINONE COMPOUNDS | 2011 |
|
RU2603140C2 |
PYRROLO-PYRROLE COMPOSITIONS AS ACTIVATORS OF PYRUVATE KINASE (PKR) | 2018 |
|
RU2736217C2 |
CONDENSED TRICYCLIC BENZIMIDAZOLE DERIVATIVES AS MODULATORS OF TNF ACTIVITY | 2014 |
|
RU2689777C1 |
BIFUNCTIONAL CYTOTOXIC AGENTS | 2015 |
|
RU2669807C2 |
TRICYCLIC HETEROCYCLIC COMPOUNDS AND JAK INHIBITORS | 2012 |
|
RU2632870C2 |
BROMODOMAIN INHIBITORS | 2017 |
|
RU2741808C2 |
SUBSTITUTED DIAMINOCARBOXAMIDE AND DIAMINOCARBONITRILE DERIVATIVES OF PYRIMIDINES, COMPOSITIONS THEREOF AND METHODS OF TREATING USE THEREOF | 2012 |
|
RU2697712C2 |
Authors
Dates
2024-08-07—Published
2019-11-01—Filed